Published March 2005 | Version v1
Journal article

Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV

  • 1. Department of Radiotherapy, Brachytherapy Unit, Institut Gustave Roussy, 39 rue Camille Desmoulins, 94805 Villejuif (France)
  • 2. Department of Radiotherapy and Radiobiology, Medical University of Vienna, Vienna (Austria)
  • 3. Department of Radiotherapy, University Hospital Gasthuisberg, Leuven (Belgium)
  • 4. Norwegian Radium Hospital, Oslo (Norway)
  • 5. Royal South Hants Hospital, Southampton (United Kingdom)
  • 6. Hopital Cantonal Universitaire de Geneve, Geneva (Switzerland)

Description

Summary: Background and purpose: Brachytherapy (BT) plays a crucial role in the management of invasive cervix cancer from stage I to IV. Intracavitary techniques are based on afterloading devices, with different types of applicators. CT and/or MRI compatible applicators allow a sectional image based approach with a better assessment of gross tumour volume (GTV) and definition and delineation of target volume (CTV) compared to traditional approaches. Accurate and reproducible delineation of GTV, CTV and PTV, as well as of critical organs has a direct impact on BT treatment planning, especially if it is possible to adapt the pear-shape isodose by optimisation using DVH analysis. When introducing a 3D image based approach for GTV and CTV assessment, there is a need for a common language to describe the concepts and to define the terms which are to be used. Methods: In 2000, GEC-ESTRO decided to support 3D imaging based 3D treatment planning approach in cervix cancer BT with the creation of a Working Group. The task was to describe basic concepts and terms and to work out a terminology enabling various groups working in this advanced field to use a common language. The recommendations described in this report were proposed based on clinical experience and dosimetric concepts of different institutions (IGR, Leuven, Vienna) and were stepwise validated against the background of different clinical experience. Conclusions: As GTV and CTV for BT change significantly during treatment, time frame for assessment of GTV and CTV for BT is specified in this report: at time of diagnosis GTVD, CTVD and at time of BT GTVB, CTVB. Furthermore, CTV for BT is defined related to risk for recurrence: high risk CTV and intermediate risk CTV. Beside verbal descriptions detailed examples are given, partly in form of schematic drawings

Additional details

Identifiers

DOI
10.1016/j.radonc.2004.12.015;
PII
S0167-8140(04)00579-1;

Publishing Information

Journal Title
Radiotherapy and Oncology
Journal Volume
74
Journal Issue
3
Journal Page Range
p. 235-245
ISSN
0167-8140
CODEN
RAONDT

INIS

Country of Publication
Ireland
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
37018756
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
AFTERLOADING; BRACHYTHERAPY; CARCINOMAS; CRITICAL ORGANS; DIAGNOSIS; EQUIPMENT; HEALTH HAZARDS; IMAGES; NMR IMAGING; OPTIMIZATION; PLANNING; RECOMMENDATIONS
Descriptors DEC
BODY; DIAGNOSTIC TECHNIQUES; DISEASES; HAZARDS; MEDICINE; NEOPLASMS; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RADIOTHERAPY; THERAPY

Optional Information

Copyright
Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.